Drug Database
Back to search

Finland· FI-REL-REL49131

Ilaris

A canakinumab product containing canakinumab, registered in Finland by Novartis Europharm Limited. The same ATC class is registered in 14 of our 19 countries.

ATC L04AC08

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedIlarisATCL04AC08REGISTER NO.FI-REL-REL49131PACKS LISTED0CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about canakinumabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Canakinumab is registered in 14 of 19 countries.

Countries holding a registration under ATC L04AC08 (canakinumab), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 9 of them publish a price we can compare per daily dose
Search canakinumab products by name

Canakinumab · ATC L04AC08

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Fimea (Finland)
Active substance
Canakinumab
Manufacturer
Novartis Europharm Limited
Country
Finland (FI)
ATC code
L04AC08
ATC class
Canakinumab
Defined daily dose
2.7 mg, P
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

374 interactions on record for canakinumab.

Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check canakinumab against other medicinesHow interaction checks work

Canakinumab · interactions on record

374 records

  • 30 severe
  • 337 moderate
  • 7 minor

Most severe, free to view

  • CladribineL01BB04severe
  • PrednisoloneA07EA01moderate
  • HydrocortisoneA07EA02moderate
  • PrednisoneA07EA03moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Canakinumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All canakinumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Ilaris
  • Liechtenstein · Ilaris
  • Norway · Ilaris

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/a0e7d661-e199-4009-8566-badc708da13e
GET /v1/drugs/a0e7d661-e199-4009-8566-badc708da13e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "2.7",
  "form": "injektioneste, liuos",
  "route": "Ihon alle",
  "ddd_unit": "mg",
  "strength": "150 mg/ml",
  "atc_label": "kanakinumabi",
  "ma_number": null,
  "auth_status": "Myyntilupa myönnetty",
  "eu_ma_number": "EU/1/09/564/004",
  "fimea_rel_id": "REL49131",
  "authorised_at": "2017-02-23"
}
API referenceMCP serverPlans

See everything about canakinumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console